Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)

• Published in: Journal of the American Academy of Dermatology Vol. 87; no. 2; pp. 351 - 358
• Main Authors: Shi, Vivian Y., Bhutani, Tina, Fonacier, Luz, Deleuran, Mette, Shumack, Stephen, Valdez, Hernan, Zhang, Fan, Chan, Gary L., Cameron, Michael C., Yin, Natalie C.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-08-2022
• Subjects: abrocitinib; atopic dermatitis; dupilumab; efficacy; response; safety; IGA; PP-NRS; AD; abrocitinib; atopic dermatitis; efficacy; dupilumab; EASI; TEAE; TH; EASI-75; JAK; response; safety; EASI-90
• ISSN: 0190-9622; 1097-6787
• DOI: 10.1016/j.jaad.2022.04.009

Abrocitinib efficacy by prior dupilumab response status in patients with moderate-to-severe atopic dermatitis has not previously been assessed in phase 3 studies.
Examine efficacy and safety of abrocitinib among patients who received prior dupilumab.
Patients with moderate-to-severe atopic dermatitis received abrocitinib 200 mg or 100 mg once daily in JADE EXTEND (phase 3 extension) after dupilumab in double-blind, placebo-controlled phase 3 JADE COMPARE.
Among prior dupilumab responders, ≥75% improvement in Eczema Area and Severity Index was achieved in 93.5% and 90.2% of patients who received 12 weeks of abrocitinib 200 mg and 100 mg, respectively; ≥4-point improvement in Peak Pruritus Numerical Rating Scale was achieved in 89.7% and 81.6%, respectively. Among prior dupilumab nonresponders, ≥75% improvement in Eczema Area and Severity Index was achieved with abrocitinib 200 mg and 100 mg in 80.0% and 67.7% and ≥4-point improvement in Peak Pruritus Numerical Rating Scale in 77.3% and 37.8%, respectively. Most common adverse events among abrocitinib-treated patients were nasopharyngitis, nausea, acne, and headache. Conjunctivitis occurred less frequently with abrocitinib in comparison to prior dupilumab.
Short-term, 12-week analysis; no placebo arm.
Efficacy and safety profile of abrocitinib in JADE EXTEND supports the role of abrocitinib as a treatment for patients with moderate-to-severe atopic dermatitis, regardless of prior dupilumab response status.